Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer

References

• Felknor SA, Delclos GL. Occupational Risk Factors. In: Textbook of Bladder Cancer. Lerner SP, Schoenberg M, Sternberg CN (Eds). Taylor & Francis, Oxon, UK 19–26 (2006).
   Google Scholar
• Yu MC, Skipper PL, Tannenbaum SR, Chan KK, Ross RK. Arylamine exposures and bladder cancer risk. Mutat. Res.506–507, 21–28 (2002).
   PubMed Web of Science ®Google Scholar
• Wu X, Lin X, Dinney CP, Gu J, Grossman HB. Genetic polymorphism in bladder cancer. Front. Biosci.12, 192–213 (2007).
   PubMed Web of Science ®Google Scholar
• Avritscher EB, Cooksley CD, Grossman HB et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology68(3), 549–553 (2006).
   PubMed Web of Science ®Google Scholar
• Konety BR, Joyce GF, Wise M. Bladder and upper tract urothelial cancer. J. Urol.177(5), 1636–1645 (2007).
   PubMed Web of Science ®Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol.54(2), 303–314 (2008).
   PubMed Web of Science ®Google Scholar
• Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update. J. Urol.178(6), 2314–2330 (2007).
   PubMed Web of Science ®Google Scholar
• Burchardt P. The flexible panendoscope. J. Urol.127(3), 479–481 (1982).
   PubMedGoogle Scholar
• Lee CS, Yoon CY, Witjes JA. The past, present and future of cystoscopy: the fusion of cystoscopy and novel imaging technology. BJU Int.102(9 Pt B), 1228–1233 (2008).
   PubMedGoogle Scholar
• van der Aa MN, Steyerberg EW, Sen EF et al. Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int.101(9), 1106–1110 (2008).
   PubMed Web of Science ®Google Scholar
• Zippe C, Pandrangi L, Potts JM et al. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res.19(4A), 2621–2623 (1999).
   PubMed Web of Science ®Google Scholar
• Smith JA, Labasky RF, Cockett ATK, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis). J. Urol.162(5) 1697–1701 (1999)
   PubMed Web of Science ®Google Scholar
• SIU. International consultation on bladder tumours. Urology66(Suppl. 6A) (2005).
   Google Scholar
• Sternberg CN, Donat SM, Bellmunt J et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology69(Suppl. 1), 62–79 (2007).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol.163(4), 1124–1129 (2000).
   PubMed Web of Science ®Google Scholar
• Au JL, Badalament RA, Wientjes MG et al. Methods to improve efficacy of intravesical mitomycin C: Results of a Randomized Phase III Trial. J. Natl Cancer Inst.93(8), 597–604 (2001).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol.174(1), 86–91 (2005).
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Sternberg CN. Treatment of metastatic urothelial cancer – opportunities for drug discovery and development. BJU Int.102(9 Pt B), 1354–1360 (2008).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a Combined Analysis of 2596 Patients from Seven EORTC Trials. Eur. Urol.49(3), 466–465 (2006).
   PubMed Web of Science ®Google Scholar
• Stenzl A, Cowan NC, De Santis M et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. DOI 10.1016/j.eururo.2009.01.002 (2009) (Epub ahead of print).
   Google Scholar
• Goh AC, Lerner SP. Application of new technology in bladder cancer diagnosis and treatment. World J. Urol.27(3), 301–307 (2009).
   PubMedGoogle Scholar
• Witjes JA, Douglass J. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin. Pract. Urol.4(10), 542–549 (2007).
   PubMedGoogle Scholar
• Frampton JE, Plosker GL. Hexyl aminolevulinate: in the detection of bladder cancer. Drugs66(4), 571–578; discussion 579–580 (2006).
   PubMed Web of Science ®Google Scholar
• Denzinger S, Burger M, Walter B et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology69(4), 675–679 (2007).
   PubMed Web of Science ®Google Scholar
• Marti A, Lange N, van den Bergh H et al. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J. Urol.162(2), 546–552 (1999).
   PubMedGoogle Scholar
• Lange N, Jichlinski P, Zellweger M et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br. J. Cancer80(1–2), 185–193 (1999).
   PubMed Web of Science ®Google Scholar
• Jichlinski P, Aymon D, Wagnieres GA et al. On the influence of the instillation time on the results of HAL (Hexvix) fluorescence detection of superficial bladder cancer. Diagnostic Optical Spectroscopy in Biomedicine II, SPIE, 5141, 272–277 (2003).
   Google Scholar
• Marti A, Jichlinski P, Lange N et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J. Urol.170(2 Pt 1), 428–432 (2003).
   PubMed Web of Science ®Google Scholar
• Jichlinski P, Guillou L, Karlsen SJ et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer – a multicenter study. J. Urol.170(1), 226–229 (2003).
   PubMed Web of Science ®Google Scholar
• Schmidbauer J, Witjes F, Schmeller N et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J. Urol.171(1), 135–138 (2004).
   PubMed Web of Science ®Google Scholar
• Jocham D, Witjes F, Wagner S et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, Phase III multicenter study. J. Urol.174(3), 862–866 (2005).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Gomella L, Fradet Y et al. A Phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J. Urol.178(1), 62–67 (2007).
   PubMed Web of Science ®Google Scholar
• Fradet Y, Grossman HB, Gomella L et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a Phase III, multicenter study. J. Urol.178(1), 68–73 (2007).
   PubMed Web of Science ®Google Scholar
• Mynderse L, Stenzl A, Denzinger S et al. Hexvix fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrences. J. Urol.181(4), 689 (2009).
   Google Scholar
• Zaak D, Kriegmair M, Stepp H et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology57(4), 690–694 (2001).
   PubMed Web of Science ®Google Scholar
• Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer104(3), 467–478 (2005).
   PubMedGoogle Scholar
• Latini DM, Hart SL, Knight SJ et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J. Urol.178(3 Pt 1), 826–831; discussion 831–822 (2007).
   PubMedGoogle Scholar
• Ullrich PM, Carson MR, Lutgendorf SK, Williams RD. Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J. Urol.169(4), 1449–1452 (2003).
   PubMed Web of Science ®Google Scholar
• Bellizzi KM, Latini DM, Cowan JE, DuChane J, Carroll PR. Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer. Urology72(6), 1269–1273 (2008).
   PubMed Web of Science ®Google Scholar
• Hart SL, Latini DM, Cowan JE, Carroll PR. Fear of recurrence, treatment satisfaction, and quality of life after radical prostatectomy for prostate cancer. Support Care Cancer16(2), 161–169 (2008).
   PubMed Web of Science ®Google Scholar
• Costanzo ES, Lutgendorf SK, Mattes ML et al. Adjusting to life after treatment: distress and quality of life following treatment for breast cancer. Br. J .Cancer97(12), 1625–1631 (2007).
   PubMed Web of Science ®Google Scholar
• Kornblith AB, Powell M, Regan MM et al. Long-term psychosocial adjustment of older versus younger survivors of breast and endometrial cancer. Psychooncology16(10), 895–903 (2007).
   PubMed Web of Science ®Google Scholar
• Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics21(18), 1315–1330 (2003).
   PubMed Web of Science ®Google Scholar
• Sievert KD, Amend B, Nagele U et al. Economic aspects of bladder cancer: what are the benefits and costs? World J. Urol.27(3), 295–300 (2009).
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol.41(5), 523–531 (2002).
   PubMed Web of Science ®Google Scholar
• Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J. Urol.165(3), 808–810 (2001).
   PubMed Web of Science ®Google Scholar
• Klan R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J. Urol.146(2), 316–318 (1991).
   PubMed Web of Science ®Google Scholar
• Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int.97(6), 1199–1201 (2006).
   PubMed Web of Science ®Google Scholar
• Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol.175(5), 1641–1644 (2006).
   PubMed Web of Science ®Google Scholar
• Kriegmair M, Zaak D, Stepp H et al. Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur. Urol.36(5), 386–392 (1999).
   PubMed Web of Science ®Google Scholar
• Riedl CR, Daniltchenko D, Koenig F et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J. Urol.165(4), 1121–1123 (2001).
   PubMed Web of Science ®Google Scholar
• Ukai R, Kawashita E, Ikeda H. A new technique for transurethral resection of superficial bladder tumor in 1 piece. J. Urol.163(3), 878–879 (2000).
   PubMed Web of Science ®Google Scholar
• Saito S. Transurethral en bloc resection of bladder tumors. J. Urol.166(6), 2148–2150 (2001).
   PubMed Web of Science ®Google Scholar
• D’Hallewin MA, Kamuhabwa AR, Roskams T, De Witte PA, Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int.89(7), 760–763 (2002).
   PubMed Web of Science ®Google Scholar
• Kubin A, Meissner P, Wierrani F et al. Fluorescence diagnosis of bladder cancer with new water soluble hypericin bound to polyvinylpyrrolidone: PVP-hypericin. Photochem. Photobiol.84(6), 1560–1563 (2008).
   PubMedGoogle Scholar
• Sim HG, Lau WK, Olivo M, Tan PH, Cheng CW. Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma? BJU Int.95(9), 1215–1218 (2005).
   PubMedGoogle Scholar
• Pan Y, Xie H, Fedder GK. Endoscopic optical coherence tomography based on a microelectromechanical mirror. Opt. Lett.26(24), 1966–1968 (2001).
   PubMed Web of Science ®Google Scholar
• Machida H, Sano Y, Hamamoto Y et al. Narrow-band imaging in the diagnosis of colorectal mucosal lesions: a pilot study. Endoscopy36(12), 1094–1098 (2004).
   PubMed Web of Science ®Google Scholar
• Bryan RT, Billingham LJ, Wallace DM. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int.101(6), 702–705; discussion 705–706 (2008).
   PubMed Web of Science ®Google Scholar
• Kruck S, Horstmann M, Gakis G et al. Virtual TUR simualtor training for novice urologists – first-time transurethral resection (TUR) of the bladder. Presented ar: EAU Annual Meeting, Stockholm, Sweden 17–21 March 2009.
   Google Scholar